STUDresearch · Peptide

Petrelintide

Also known as

ZP8396 · Zealand amylin · Roche / Zealand amylin analog · pertrelintide (common misspelling in press)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Peptide Niche talk Systemic SubQ Metabolic / GLP-1 class

Systemic once-weekly long-acting amylin analog (Zealand, partnered with Roche).

What people say Petrelintide (ZP8396) is Roche/Zealand’s investigational long-acting amylin analog for weight management. It is different from eloralintide and cagrilintide, and is not a GLP-1/GIP product or an approved gray-vial equivalent of the trial drug. Doses people talk about

Earlier Phase 1b arms0.6 / 1.2 mg weekly SC

Six-week study exposures. These are petrelintide amounts, not pramlintide or eloralintide equivalents.

Later Phase 1b target arms2.4 / 4.8 / 9.0 mg weekly SC

Sixteen-week design with staged dosing, not 16 full weeks at every target amount. The warning against copying eloralintide’s 9 mg remains important.

Phase 2 used five weekly SC levels with roughly four-week steps; the initial announcement did not list every arm’s milligrams. Its schedule and future combination plans do not create a self-use ladder.

Half-life & effect duration

Half-life in the body: Under-the-skin injectionAbout 213–257 hours — roughly 9–11 days
IV studyAbout 239 hours — roughly 10 days
Felt duration people report: Felt durationNo consistent firsthand appetite or symptom window reported
Trial tolerabilityLess nausea reported after reaching maintenance

Timing context & sources

How it may feel Discussion weighs modest double-digit trial weight loss against tolerability. Nausea still occurred more often than with placebo; less nausea after maintenance is a sponsor-reported pattern. The opened detailed amylin experience was about eloralintide, not a petrelintide diary.

Cycles people discuss Phase 1b studied six- and 16-week exposure; Phase 2 continued weekly treatment for 42 weeks, with a 28-week primary endpoint and safety follow-up to week 51. Future Phase 3 or combination plans are not consumer on/off cycles. Timing Phase 2 used once-weekly SC dosing with steps about every four weeks and continued treatment to about week 42; safety follow-up ran to week 51. These are trial intervals, not a consumer cycle. Stacks ZUPREME-1 tested petrelintide alone with lifestyle measures. The proposed CT-388/enicepatide combination is a separate development program; comparisons with eloralintide, cagrilintide and tirzepatide are not evidence for stacking them. Watch for Unapproved. Gray label ≠ ZUPREME drug.

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

Clinical petrelintide: 213–257-hour mean terminal half-life after single SC doses.

The IV cohort estimate was 239 hours; median SC Tmax was 28–108 hours.

Small Phase 1 cohorts; not a gray-vial specification or subjective appetite clock.

Brændholt Olsen et al. (2026): two petrelintide Phase 1 trials (opens in a new tab)Full-text XML actually retrieved through Europe PMC /webservices/rest/PMC13243934/fullTextXML: Trial Design and Participants, Endpoints/PK assay, Results Pharmacokinetics paragraphs and Figure 2 context; safety Results/Discussion.PMC browser check and Wiley timeout prevented normal HTML access; Europe PMC primary full text was read. Healthy-weight/overweight males in SAD; later MAD populations differ. Results apply to clinical petrelintide, not gray vials or eloralintide.

Felt duration people report

Petrelintide’s subjective onset-to-offset duration is not established by these discussions.

Sponsor data describe less nausea after maintenance; community comparisons concern tolerability and hoped-for alternatives.

Other amylin and GLP-1 experiences are not petrelintide logs. Trial weight endpoints and multi-day plasma exposure cannot supply a personal felt duration.

Danish community debate about the petrelintide Phase 2 readout (opens in a new tab)Opening 10.7%/42-week discussion; Ok_Sir_6633 and Chuth2000 exchanges, later same-author market-view updates, and New_Swimmer2180 comment about prior GLP-1 intolerance.Danish-language investor/community discussion, not petrelintide treatment logs. The first-person intolerance report concerns a GLP-1 drug, not petrelintide. Comparative efficacy and “near-zero” adverse-effect rhetoric are opinions, not measured facts.
Other amylin agonists? Community identity boundary (opens in a new tab)Opening comparison of cagrilintide, eloralintide, petrelintide and pramlintide; sha1222/ HairPsychological617 nested trial question and same-author experience follow-up.The 60-pound loss, fatigue, constipation and 11-day assertion follow an eloralintide/Lilly trial question. They are not petrelintide evidence. Only visible branches read; no absorbed-dose or product assay.
Zealand March 2026 ZUPREME-1 topline release (opens in a new tab)Company announcement 3/2026, 2026-03-05: tolerability paragraphs, maintenance nausea statement and About ZUPREME-1 treatment/follow-up schedule.Sponsor topline disclosure, not a head-to-head comparison or a patient diary. The maximally effective arm is different from pooled treatment percentages.

Other context in this card

Zealand June 2026 ZUPREME-1 ADA release (opens in a new tab)Press release 13/2026, June 5: trial description (485 randomized; 493 enrolled in About section), Key Findings, and 28/42/51-week endpoint/follow-up distinctions.Sponsor-authored release reproduced by MFN; not the full final Phase 2 paper. Pooled GI percentages and most-effective-arm claims are not identical populations.
Zealand petrelintide pipeline page (opens in a new tab)Clinical development section: Phase 1b part 1/2 quantities and durations, Phase 3 planned second half 2026, and explicit investigational status.Sponsor development page; forward-looking timing is not proof a trial has started. This is not approval or a community-use product specification.
Zealand petrelintide/CT-388 pipeline page (opens in a new tab)Clinical development section and fixed-dose combination description; page still describes an expected first-half-2026 Phase 2 initiation.Page wording is a dated expectation, not verification of current recruitment or a completed combination trial. No unsupervised stacking conclusion follows.

What people say 6

Analyst split: “10.7% is mid” vs “if people can stay on it, that wins.” That argument is the social layer. forum
ZUPREME-1 (42 wk): Up to 10.7% mean loss vs 1.7% placebo (efficacy estimand). All five arms beat placebo at the 28-week primary. trial
The GI headline: Across petrelintide treatment arms, nausea was reported in 19.6% versus 6.2% on placebo and vomiting in 3% versus 6.2%; diarrhea/constipation stayed in single digits near placebo. Separately, the maximally effective arm had no vomiting or GI discontinuations. Nausea was not placebo-equal, and these are not head-to-head Zepbound results. trial
Dose-escalation completion: ~88–98% reached maintenance — the number forums contrast with brutal GLP titrations. trial
Waist / lipids / hsCRP: Secondary cuts (waist ~8–11 cm, triglycerides down, hsCRP down) in the ADA 2026 package. trial
Phase 1b: 0.6 / 1.2 mg × 6 weeks ~5%; later 2.4 / 4.8 / 9.0 mg weekly for 16 weeks ~4.8 / 8.6 / 8.3% vs 1.7% placebo. trial

Doses people talk about 4

PeptIQ-style explainers: “Five arms, weekly, escalate ~q4wk.” They also say do not buy a research vial as if it were ZUPREME product. forum
Do not copy Elo 9 mg onto this molecule. Different analog. forum
Phase 1b anchors people still quote: 0.6 and 1.2 mg weekly; later 2.4 / 4.8 / 9.0 mg weekly. trial
No approved dose. Phase 2 used five once-weekly SC levels, stepped about every 4 weeks. Exact mg per arm were not all in the first press notes. trial

How it may feel 5

Public experience boundary: The retained feel timeline combines trial adverse-event timing with amylin-class discussion, not a mature petrelintide self-experiment diary layer. In the opened amylin thread, the detailed trial follow-up was about eloralintide; in the readout debate, prior GLP-1 intolerance was not petrelintide exposure. forum
Vs a GLP start: Rooms expect less vomit, less “can’t look at food.” That is a hope imported from the table, not a thousand Reddit diaries. forum
If you see a gray vial: Treat “how I feel on petrelintide” as identity-unknown until the field has a real logbook. forum
Escalation (every ~4 weeks in Phase 2): Mild nausea on the way up; “almost no nausea after maintenance” in the Roche/Zealand telling. trial
Weeks 4–28 discussion: Every Phase 2 arm had weight reduction versus placebo at the 28-week primary endpoint. That endpoint does not establish when a person first felt appetite change, and it is not evidence for a 2% week-one shock. trial

Cycles people discuss 3

Phase 2 course: Once-weekly treatment continued to about 42 weeks; the primary weight endpoint was at week 28 and safety follow-up continued to week 51. These are study windows, not a consumer cycle. trial
Phase 3 not a consumer cycle. Planned 2H 2026 start in company talk. trial
Combo with enicepatide is a mid-2026 Phase 2 plan, not a stack to run. trial

Timing 3

Weekly treatment design: Repeated-dose trials use once-weekly SC petrelintide. Phase 1 also included a single 0.35 mg IV research cohort, so “every public protocol” should not be read as excluding that experimental route. trial
Published human PK: The 2026 Phase 1 paper reports mean terminal half-lives of 213–257 hours after single SC doses and 239 hours after IV dosing; median SC Tmax was 28–108 hours. Repeated-dose steady state was reached after the fifth dose. These plasma measures replace the older no-day-count uncertainty, not a felt-duration estimate. trial
Trial step intervals versus clearance: Phase 2 used four-week steps, slower than the two-week Phase 1b steps; the sponsor described less nausea and almost none after maintenance. This is between-study tolerability context, not proof that step speed alone caused the difference or a measured duration of appetite suppression. trial

Stacks 3

Mental compare stack: vs eloralintide, cagrilintide, tirz. forum
Solo in ZUPREME-1. trial
Planned + enicepatide (CT-388) — Roche obesity combo, not a Discord default. trial

Storage notes 1

No mix chart. There is no honest community SOP yet. forum

Related 7

Watch for 5

Not a free lunch at 10.7%. Analysts already said the % may lose to tirz/elo/reta. forum
Unapproved. Gray label ≠ ZUPREME drug. forum
Combination caution: The petrelintide/CT-388 Phase 2 start was described as a first-half/mid-2026 plan; that dated statement does not establish current trial completion or a usable stack. Do not pre-stack with CT-388 from a press release. forum
Class obesity cautions if weight falls fast (gallbladder, under-fuel). forum
Nausea (usually mild) on the way to maintenance. trial

Updated: 2026-08-17

Evidence mix More trial/lab tags than forum tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.

↑ Back to top

Half-life & effect duration

Timing context & sources⌄

Half-life in the body

Felt duration people report

Other context in this card

What people say 6

Doses people talk about 4

How it may feel 5

Cycles people discuss 3

Timing 3

More on what it is 6

Stacks 3

Storage notes 1

Related 7

Watch for 5

Timing context & sources